Background and objective: A new taxonomic and management approach, termed treatable traits, has been proposed for airway diseases including severe asthma. This study examined whether treatable traits could be identified using registry data and whether particular treatable traits were associated with future exacerbation risk.
INTRODUCTION
Severe asthma is a heterogeneous disease of the airways that is complicated by frequent attacks and comorbidities. A 2017 Lancet commission proposed that the current concept of airway diseases fails to recognize the complexity of disease and does little to promote individualized management. 1 To address this issue, a new approach has been proposed that characterizes individuals with airway diseases by the presence of potentially modifiable elements that impact symptoms and prognosis, called treatable traits. [2] [3] [4] Management is subsequently individually tailored to directly target these identified traits. A treatable trait is defined as a phenotypic or endotypic characteristic that can be successfully targeted with treatment. 3 In COPD 5 and in older patients with airway diseases, 6 this approach shows great promise; however, its usefulness in severe asthma has not been established.
Furthermore, while the method of assessing treatable traits has been described [1] [2] [3] and applied in ambulatory research clinics, 5, 6 the assessment of treatable traits in other clinically relevant settings is unknown. Severe asthma registries are used to describe disease characteristics and treatment responses in a real-life clinic setting and therefore represent an emerging data source that complements efficacy data. It is not known whether severe asthma registries can be used to identify treatable traits in severe asthma, nor whether these traits are able to predict future risk of asthma attacks.
Our first aim was to determine whether the identification of treatable traits is possible using a severe asthma registry. Second, we aimed to assess the prevalence of treatable traits in severe asthma compared with non-severe asthma, and to assess the relationship between treatable traits and future exacerbation risk. We hypothesized that treatable traits could be recognized using severe asthma registry data and that they would predict future asthma exacerbation risk.
METHODS
The Severe Asthma Web-Based Database (SAWD) is a multicentre study across 26 sites in Australia, New Zealand and Singapore launched by the Australasian Severe Asthma Network under the governance of the Thoracic Society of Australia and New Zealand. SAWD comprises a cross-sectional evaluation of patient characteristics and a 2-year prospective cohort study.
Included in the registry were adults with severe asthma, confirmed by variable airflow limitation (AFL) within the last 10 years and poor control 7 despite highdose inhaled corticosteroids (ICS) and a second controller (Appendix S1, Supplementary Information). Inhalation technique, education, adherence and written action plan (WAP) had to be optimized prior to inclusion. A group with non-severe asthma with proven variable AFL, controlled stable disease and maintenance ICS therapy were included as a comparison group. Participants with non-severe asthma were recruited via approved research databases and investigators' clinical practices. A primary diagnosis of lung disease other than asthma, cognitive impairment, current malignancy, an inability to attend visits and pregnancy were exclusions.
Ethical approval was obtained from relevant human research ethics committees or institutional review boards, according to country-specific requirements (lead HNEHREC 12/11/21/4.04). All participants provided written, informed consent.
SUMMARY AT A GLANCE
We assessed the prevalence of treatable traits in severe asthma compared with non-severe asthma, and assessed the relationship between treatable traits and future exacerbation risk. We demonstrate the usefulness of the treatable traits approach in severe asthma and which specific treatable traits are predictive of future asthma attacks.
Registry assessments
Demographic characteristics, medication use, asthma and co-morbidity history, asthma control (Asthma Control Questionnaire, 6-item, ACQ6 8 ), asthma quality of life (Asthma Quality of Life Questionnaire, AQLQ 9 ) and anxiety and depression (Hospital Anxiety and Depression Scale; HADS 10 ) were assessed at baseline. Participants underwent spirometry, allergen skin-prick tests and blood tests (full-blood count, total and specific IgE). Exhaled nitric oxide and induced sputum were optional. Past-year exacerbations were identified using a standardized assessment as defined previously. 11 Additional clinical investigations performed within the last 5 years were logged in the database, including polysomnography, 24-h oesophageal pH monitoring, computed tomography (CT) of the chest, sinus CT, oesophagoscopy and laryngoscopy.
Database analysis
Cross-sectional baseline data were used to determine the prevalence of treatable traits. Treatable traits were risk factors and management issues associated with asthma that were identifiable and could be targeted for management. We conducted a mapping exercise where traits proposed by Gibson et al. 2 and Agusti et al. 3 were compared with data fields from SAWD. If <10% of the sample had a valid assessment for a trait, it was excluded from analysis.
Statistical analysis
Descriptive statistics were computed and differences between severe and non-severe asthma compared using Fisher's exact test, Student's t-test or Wilcoxon rank sum test, as appropriate. To account for the varying total number of traits reported in each individual, the number of treatable traits identified was expressed as the proportion of identified traits over the number of traits assessed. Spearman's correlations were performed to examine the intercorrelation between multiple traits (Table S1 , Supplementary Information).
Treatable traits were entered into separate negative binomial regression analyses to predict the number of exacerbations during follow-up, offset by duration of follow-up data available and clustering standard errors by study site. A secondary, multivariable analysis was conducted to adjust for confounding. Covariates were selected for inclusion using a causal diagram (directed acyclic graph (DAG); Appendix S1, Fig. S1 (Supplementary Information)). The DAG was created using known evidence-based causal/association pathways.
To examine how multiple treatable traits predict exacerbations over time, that is by including all traits, negative binomial Bayesian Model Averaging (BMA) was conducted 12 (Appendix S1, Supplementary Information). From the analysis, we reported the best 154 models of the data, illustrated in a heat-map, to demonstrate the proportion of models in which each predictor was included, known as the posterior inclusion probability.
BMA was conducted in the R programming environment (R Foundation, Vienna, Austria) using the bic.glm command of the BMA package, 13 with Occam's window algorithm and a uniform prior distribution. Other analyses were conducted in Stata IC/15 (StataCorp LLC, College Station, TX, USA). The significance level for frequentist analyses was set at 0.05.
RESULTS

Baseline characteristics
There were 434 individuals with severe and 102 individuals with non-severe asthma who completed the crosssectional assessment between July 2013 and April 2017. Groups were similar demographically, with a predominance of women (Table 1) .
Treatable traits identification
The prevalence of 24 treatable traits could be assessed using information contained in the database; 18 identified by Agusti et al. 3 and additional traits identified by Gibson et al. 2 The assessments and definitions used for identification are shown in Table 2 . 2, 6 As asthma management skills were optimized in the severe asthma group prior to registry entry, these traits were excluded from analysis. Bacterial colonization was also excluded due to insufficient data. The treatable traits domains are pulmonary (7 traits), extrapulmonary (13 traits) and behavioural/risk factors (4 traits). The traits were independently coded in a subset of 343 SAWD participants by two authors (K.G., S.A.H.). Inter-rater reliability was very high for most traits (agreement: 90-100%; kappa: 0.80-1.00) and satisfactory for upper airway disease (kappa AE SE: 0.71 AE 0.05), cardiovascular disease (CVD) (0.74 AE 0.05) and inhaler device polypharmacy (0.51 AE 0.05) (Table S2 , Supplementary Information).
Treatable traits prevalence
The median (interquartile range, IQR) number of traits assessed out of a possible 24 was 22 (20) (21) (22) (23) in the severe group and 22.5 (21) (22) (23) in the non-severe group.
Participants with severe asthma expressed a median of 29% (IQR: 22-37%) of the possible traits assessed and non-severe asthma expressed 19% (IQR: 14-27%, P < 0.001) (Fig. 1A) . Individuals with severe asthma had more pulmonary (33%, IQR: 17-50%) and extrapulmonary traits (25%, IQR: 15-38%) compared with nonsevere asthma (17%, IQR: 0-33%, P < 0.001; 15%, IQR: 8-27%, P < 0.001, respectively). The proportion of traits expressed in the behavioural/risk factor domain was similar between groups (both were 25%).
The prevalence of the individual traits is shown in Table 2 and Figure 1B -D. The following traits were significantly more prevalent in severe asthma than nonsevere: incompletely reversible AFL, being prone to exacerbation, neutrophilic airway inflammation, obesity, vocal cord dysfunction (VCD), obstructive sleep apnoea (OSA), depression, systemic inflammation, gastrooesophageal reflux disease (GORD), inhaler device polypharmacy and Aspergillus sensitization ( Table 2) .
Treatable traits and exacerbation risk
The severe asthma group reported more baseline pastyear exacerbations (P < 0.001), irrespective of exacerbation type (Table S3 , Supplementary Information). During prospective follow-up, participants with severe asthma also reported more exacerbations (median (IQR): 2 (0, 4.1)) compared to those with non-severe asthma (0 (0, 2.0), P < 0.001). Sensitivity analyses excluding participants on omalizumab or mepolizumab at any assessment (n = 108) did not change exacerbation findings.
To identify treatable traits predictive of future exacerbation risk we created a DAG, which was informed by current knowledge of possible causal and therefore potentially treatable risk factors (Fig. S1 , Supplementary Information). These associations were tested in regression models, and each of the traits were measured as the ratio of the rate of exacerbations in the trait-positive group to the rate in the trait-negative group, and summarized as the incidence rate ratio (IRR). For each additional trait present, there was a 13% increase in exacerbation risk (P < 0.001; Table 3 ). The magnitude of risk was similar within the pulmonary and extrapulmonary domains (IRR: 1.16, P = 0.018; IRR: 1.15, P < 0.001, respectively). Of the pulmonary traits, eosinophilic inflammation and being prone to exacerbation were associated with future exacerbation risk. The extrapulmonary traits of upper airway disease, VCD, OSA, depression, anxiety, underweight and systemic inflammation were associated with increased exacerbation risk, as was inhaler device polypharmacy. Figure 2 illustrates the modified DAG, presenting only those traits that significantly increased exacerbation risk over time. Similarly, sensitivity analysis representing trait severity largely did not change the results (Table S4 , Supplementary Information).
In evaluating predictors of future exacerbations, we also considered all treatable traits together in a BMA analysis. Being prone to exacerbations prior to study entry, number of follow-up visits completed, inhaler device polypharmacy, OSA, age and depression emerged as the best predictors of exacerbation risk in patients with severe asthma (Fig. 3 , Table S5 (Supplementary Information).
DISCUSSION
Using a severe asthma registry database, we identified the prevalence of 24 treatable traits. Many pulmonary Treatable traits in severe asthma and extrapulmonary traits were significantly more prevalent in severe asthma, demonstrating the additional burden experienced by this group. Importantly, we also identified the treatable traits that predicted increased future exacerbation risk, highlighting the clinical utility of this approach. We defined treatable traits as relevant characteristics of airway diseases that can be targeted for individualized management. This definition is consistent with the concepts described by Agusti et al. 3 and in our prior work. 6 Of the 24 traits identified in the registry, five were not included in Agusti et al.'s proposal: prone to exacerbation, neutrophilic inflammation, Aspergillus sensitization, osteoporosis and anaemia. They were however found in other related management approaches 2, 6, 14, 15 and fulfilled our definition of treatable traits. If this new taxonomic system is to be adopted, we will need to reach a consensus on which treatable traits, identified thus far, are important in airway disease management. Data from this study can be used to inform this discussion.
This study reports the prevalence of treatable traits using a severe asthma registry, and importantly, describes the usefulness of this approach in severe asthma. Cross-sectional characterization studies of other severe asthma cohorts have been previously published, [16] [17] [18] [19] [20] [21] but reporting of co-morbidities was limited in most. Some other studies of systematic assessments in severe asthma were more comprehensive. [22] [23] [24] [25] In agreement with these, we found that a substantial proportion of patients presented with allergic sensitization, upper airway disease, eosinophilic inflammation, obesity, GORD, psychological issues and repeated exacerbations. [16] [17] [18] [19] [20] 23, 25 The number of identified traits in the behavioural/ risk factors domain were not more prevalent in severe asthma, and an increasing number of traits in this domain did not increase exacerbation risk. However, these data should be interpreted with caution, as traits that are known to be associated with poorer outcome, such as inadequate inhaler technique, non-adherence and lack of a WAP, were not included in these analyses, since these skills were optimized before study entry. Other behavioural traits may not be readily reported by patients.
Exacerbations of severe asthma are common and have negative impacts on health outcomes. 26 Exacerbation avoidance is key to management, with the Lancet commissioners for Redefining Airways Disease calling for zero tolerance on attacks. 1 We found that during prospective follow-up, the median rate of attacks was two/person/year, and in severe asthma the exacerbation rate was 2.36 times that of nonsevere asthma. We sought to determine treatable trait predictors for future exacerbations, in order to inform key targets for future research. We did this in two ways, first we considered traits that were known to be associated or have a causal relationship with attacks. We tested the associations in regression models; in some cases, the trait had a direct link to exacerbations and, in others, it was via a linked pathway to exacerbations (Fig. S1, Supplementary Information) . This novel analysis identified traits associated with increased exacerbation risk including VCD, raising the question of whether some of these exacerbations were actually VCD episodes. Anxiety, depression, upper airway disease, OSA and eosinophilic inflammation were also associated with exacerbation risk, as has been previously reported in severe asthma and/or COPD. 27, 28 Interestingly, inhaler device polypharmacy and being underweight emerged as predictors despite no direct or indirect link proposed in the DAG. These results highlight important traits that could be targeted in an effort to reduce attacks, informing future clinical trials.
Our second approach for examining exacerbation predictors was the use of BMA. The best of all models involved the predictors of being prone to exacerbation, number of visits completed, inhaler device polypharmacy and OSA. Being exacerbation prone at baseline and Prevalence of treatable traits, separated as (B) pulmonary traits, (C) extrapulmonary traits and (D) behavioural traits and risk factors ( , non-severe asthma; , severe asthma). *P < 0.05; **P < 0.01; ***P < 0.001. GORD, gastro-oesophageal reflux disease; OSA, obstructive sleep apnoea; VCD, vocal cord dysfunction.
Respirology ( Treatable traits in severe asthma number of visits predicts future exacerbation risk in every model. Inhaler device polypharmacy, OSA and depression were also frequently included in the top 154 models, indicating their importance as predictors of exacerbation risk, over and above a history of frequent exacerbations and amount of follow-up time. This is important, as whilst some of these traits may be assessed (e.g. depression) as part of severe asthma systematic assessment, others are not (e.g. OSA and inhaler device polypharmacy), and all are infrequently treated. 21 OSA, inhaler device polypharmacy and depression were significant predictors in both approaches we employed, suggesting concordance of these approaches.
A criticism or counter argument to the treatable trait approach is its complexity and the resources required to implement the range of assessments recommended. Proponents of the approach have suggested that strategies are needed to enable the identification of treatable traits that contribute to poor respiratory health in patients, and be treated accordingly. 29 Our analyses have provided important new knowledge in terms of identifying the treatable traits that matter, at least in terms of exacerbation avoidance. We recognize that the implementation of the treatable traits approach, and the design of randomized controlled trials that aim to test the approach are complex, but necessary. As such, these analyses are important for the progress of research in the area. Identifying the traits that have a large impact informs the design of intervention studies that aim to improve outcomes, including exacerbations. For example, in developing a multicomponent intervention one might start with the traits that predict poor outcome. Another interesting analysis for a prospective treatment study would be to determine if any traits were associated with an improved outcome.
Clinicians and researchers recognize that severe asthma is a heterogeneous disease associated with multiple comorbidities and behavioural traits, and international guidelines recommend that a systematic assessment is implemented. 7 We previously performed a systematic review and meta-analysis of multidimensional assessment in severe asthma 21 and report that this approach is associated with improvements in health status, asthma control and exacerbations. However, it is also evident that many traits that we have identified as prevalent and associated with future risk are frequently not assessed in severe asthma populations. 21 This present study reports the application of a multidimensional assessment in severe asthma that demonstrates clinical utility and allows the recognition of important traits that predict outcome. It is also clinically feasible, and shows how the use of registry data can be used to inform treatment.
While the registry database provided a large sample size, it had its limitations. The number of traits assessed was limited by the information contained in the database. Hence, some relevant traits could not be evaluated. Most traits were assessed systematically but optional clinical tests that were negative may have been omitted. Physician or self-reported co-morbidities may have underestimated and overestimated prevalence. Like any other registry, missing data was also limiting. In our study, each participant had a median of 2 traits out of 24 missing from the database. To account for the varying number of traits assessed, we reported proportions of identified traits and used this as the basis of our comparisons. Finally, we identified treatable traits based on published recommendations Figure 2 Modified directed acyclic graph depicting treatable traits significantly (P < 0.05) associated with increased risk of exacerbations over time. Numbers are the incident rate ratios (IRR) and 95% confidence intervals for the total effect of each trait on exacerbations over time.
related to this concept. 2, 3 Most of these traits are supported by evidence-based treatment recommendations. For some traits, however, such as systematic inflammation and neutrophilic airway inflammation, the evidence to support current treatment strategies is less developed. Similarly, there is also some debate about what is and is not a treatable trait, for example is AFL in severe asthma treatable? We propose that further international consensus is required to determine the accepted treatable traits and their biomarkers.
In conclusion, we have demonstrated that data collected after systematic characterization of asthma patients may be used to identify treatable traits, and we have identified important traits that predict future exacerbation. The results confirm the marked heterogeneity and greater burden associated with severe asthma and reinforce the need for systematic assessment in patients with severe asthma, although the process for translation to clinical practice needs to be defined. Trials evaluating the efficacy and cost-effectiveness of different assessments and interventions are duly needed so that we can define 'treatable traits that matter'. Appendix S2 Declaration of interests. Figure S1 Directed acyclic graph showing relationships between treatable traits in predicting exacerbations. Table S1 Correlation between traits, with positive correlations denoted in blue and negative correlations in orange. Table S2 Proportion agreement and kappa interrater reliability of two independent coders of each treatable trait within a subset of SAWD participants. Table S3 Exacerbations at baseline and across followup by severity status. Table S4 Association between continuous traits at baseline and exacerbations over follow-up. Table S5 Pooled incident rate ratios and 95% CI and posterior inclusion probability in models (Bayesian Model Averaging). Visual Abstract Treatable Traits predict future attacks in severe asthma.
